Page last updated: 2024-11-04

tegafur and Kidney Failure

tegafur has been researched along with Kidney Failure in 8 studies

Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.

Research Excerpts

ExcerptRelevanceReference
" We aimed to develop a pharmacokinetic model to describe the kinetics of tegafur and 5-FU after the administration of TS-1 and UFT."2.73Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. ( Hori, S; Inoue, S; Ohtani, H; Sawada, Y; Tsujimoto, M, 2007)
" However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients."2.50Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'. ( Fujita, K; Sasaki, Y, 2014)
"S-1 plus oxaliplatin in advanced gastric cancer patients with impaired renal function appears safe and has demonstrated efficacy given appropriate dose modification."1.56Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study. ( Bando, H; Demachi, K; Kawasaki, T; Nomura, H; Shitara, K; Yamaguchi, M; Yoshino, T, 2020)
"We conducted a prospective pharmacokinetic study to develop an S-1 dosage formula based on renal function."1.43Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. ( Boku, N; Booka, E; Gomi, D; Hamamoto, Y; Ichiyama, T; Imamura, CK; Kawakubo, H; Kitagawa, Y; Mizukami, T; Soejima, K; Takahashi, T; Takeuchi, H; Tanigawara, Y; Tateishi, K, 2016)
" These findings demonstrate that administration of S-1 to patients with impaired renal function may need individualized dosing and pharmacokinetic monitoring."1.31Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ( Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masutani, S; Satomi, T; Shimizu, J; Tatsuta, M, 2002)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's4 (50.00)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Demachi, K1
Bando, H1
Nomura, H1
Shitara, K1
Yoshino, T1
Yamaguchi, M1
Kawasaki, T2
Takeuchi, M1
Imamura, CK2
Booka, E2
Takeuchi, H2
Mizukami, T2
Kawakami, T1
Funakoshi, T1
Wakuda, K1
Aoki, Y1
Hamamoto, Y2
Kitago, M1
Kawakubo, H2
Boku, N2
Tanigawara, Y2
Kitagawa, Y2
Miyagawa, F1
Sugano, Y1
Sho, M1
Asada, H1
Fujita, K1
Sasaki, Y1
Gomi, D1
Ichiyama, T1
Tateishi, K1
Takahashi, T1
Soejima, K1
Yamazaki, T1
Tahara, M1
Enokida, T1
Wakasugi, T1
Arahira, S1
Zenda, S1
Motegi, A1
Akimoto, T1
Yoshisue, K1
Ikeda, M1
Furukawa, H1
Imamura, H1
Shimizu, J1
Ishida, H1
Masutani, S1
Tatsuta, M1
Satomi, T1
Inoue, S1
Ohtani, H1
Tsujimoto, M1
Hori, S1
Sawada, Y1

Reviews

1 review available for tegafur and Kidney Failure

ArticleYear
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
    Drug metabolism and pharmacokinetics, 2014, Volume: 29, Issue:1

    Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationsh

2014

Trials

3 trials available for tegafur and Kidney Failure

ArticleYear
Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application.
    Cancer science, 2021, Volume: 112, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Combinations; Female;

2021
Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer-effect of renal insufficiency.
    Japanese journal of clinical oncology, 2017, May-01, Volume: 47, Issue:5

    Topics: Aged; Area Under Curve; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Female; Head

2017
Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
    Drug metabolism and pharmacokinetics, 2007, Volume: 22, Issue:3

    Topics: Administration, Oral; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemother

2007

Other Studies

4 other studies available for tegafur and Kidney Failure

ArticleYear
Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study.
    Japanese journal of clinical oncology, 2020, Feb-17, Volume: 50, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dose-Response R

2020
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
    European journal of dermatology : EJD, 2017, 12-01, Volume: 27, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluo

2017
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016, Volume: 19, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; H

2016
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:1

    Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cisplatin; Disease Models, Animal; Drug Combinations

2002